High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model

Stem Cell Reviews and Reports

Volumn 13, Issue 3, 2017, Pages 335-346

  Conant, Genevieve ^a,b   Lai, Benjamin Fook Lun ^a   Lu, Rick Xing Ze ^a   Korolj, Anastasia ^a,b   Wang, Erika Yan ^a   Radisic, Milica ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Cardiotoxicity; Drug screening; Heart on a chip; Kinase; Organ on a chip

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; NILOTINIB; SORAFENIB; SUNITINIB; TRASTUZUMAB; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CARDIAC MAPPING SYSTEM; CARDIAC MUSCLE CELL; CARDIOTOXICITY; CELL MIGRATION; CELL PROLIFERATION; DRUG SCREENING; HEART DEVELOPMENT; HEART FUNCTION; HEART INFARCTION; HEART ON A CHIP; HIGH THROUGHPUT SCREENING; INDUCED PLURIPOTENT STEM CELL; LAB ON A CHIP; MONOLAYER CULTURE; OPTICAL BIOSENSOR; PATCH CLAMP TECHNIQUE; PRIORITY JOURNAL; TISSUE ENGINEERING; TUMOR INVASION; ANIMAL; BIOLOGICAL MODEL; CARDIAC MUSCLE; DEVICES; HUMAN; METABOLISM; PRECLINICAL STUDY; PROCEDURES;

ANIMALS; DRUG EVALUATION, PRECLINICAL; HUMANS; LAB-ON-A-CHIP DEVICES; MODELS, CARDIOVASCULAR; MYOCARDIUM;

EID: 85018485197     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-017-9736-2     Document Type: Article

References (116)

1. DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20–33.
2. Mullard, A. (2015). 2014 FDA drug approvals. Nature Reviews. Drug Discovery, 14(2), 77–81.
3. Research C for DE and. Drug Innovation - Novel Drugs Summary 2016 [Internet]. [cited 2017 Apr 4];Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm534863.htm
4. Kola, I., & Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Reviews. Drug Discovery, 3(8), 711–716.
5. Arrowsmith, J., & Miller, P. (2013). Trial watch: Phase II and phase III attrition rates 2011-2012. Nature Reviews. Drug Discovery, 12(8), 569–569.
6. Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., et al. (2010). How to improve R&D productivity: The pharmaceutical industry’s grand challenge. Nature Reviews. Drug Discovery, 9(3), 203–214.
7. Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663–676.
8. Yang, X., Rodriguez, M., Pabon, L., et al. (2014). Tri-iodo-l-thyronine promotes the maturation of human cardiomyocytes-derived from induced pluripotent stem cells. Journal of Molecular and Cellular Cardiology, 72, 296–304.
9. Radisic, M., Park, H., Shing, H., et al. (2004). Functional assembly of engineered myocardium by electrical stimulation of cardiac myocytes cultured on scaffolds. Proceedings of the National Academy of Sciences, 101(52), 18129–18134.
10. Zhang, D., Shadrin, I. Y., Lam, J., Xian, H.-Q., Snodgrass, H. R., & Bursac, N. (2013). Tissue-engineered cardiac patch for advanced functional maturation of human ESC-derived cardiomyocytes. Biomaterials, 34(23), 5813–5820.
11. Nunes, S. S., Miklas, J. W., Liu, J., et al. (2013). Biowire: A platform for maturation of human pluripotent stem cell-derived cardiomyocytes. Nature Methods, 10(8), 781–787.
12. Hartman, M. E., Dai, D.-F., & Laflamme, M. A. (2016). Human pluripotent stem cells: Prospects and challenges as a source of cardiomyocytes for in vitro modeling and cell-based cardiac repair. Advanced Drug Delivery Reviews, 96, 3–17.
13. Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100(1), 57–70.
14. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674.
15. Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002). The protein kinase complement of the human genome. Science, 298(5600), 1912–1934.
16. Fabbro D, McCormick F. (2007) Protein Tyrosine Kinases: From Inhibitors to Useful Drugs. Springer Science & Business Media.
17. Krause, D. S., & Van Etten, R. A. (2005). Tyrosine kinases as targets for cancer therapy. The New England Journal of Medicine, 353(2), 172–187.
18. Vlahovic, G., & Crawford, J. (2003). Activation of tyrosine kinases in cancer. The Oncologist, 8(6), 531–538.
19. Nicol, D., Hii, S.-I., Walsh, M., et al. (1997). Vascular endothelial growth factor expression is increased in renal cell carcinoma. The Journal of Urology, 157(4), 1482–1486.
20. Davies, H., Bignell, G. R., Cox, C., et al. (2002). Mutations of the BRAF gene in human cancer. Nature, 417(6892), 949–954.
21. Salesse, S., & Verfaillie, C. M. (2002). BCR/ABL: From molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia. Oncogene, 21(56), 8547–8559.
22. Pulford, K., Lamant, L., Espinos, E., et al. (2004). Oncogenic protein tyrosine kinases: The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cellular and Molecular Life Sciences, 61(23), 2939–2953.
23. Chen, M. H., Kerkelä, R., & Force, T. (2008). Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation, 118(1), 84–95.
24. Force, T., & Kolaja, K. L. (2011). Cardiotoxicity of kinase inhibitors: The prediction and translation of preclinical models to clinical outcomes. Nature Reviews. Drug Discovery, 10(2), 111–126.
25. Will, Y., Dykens, J. A., Nadanaciva, S., et al. (2008). Effect of the Multitargeted tyrosine kinase inhibitors Imatinib, Dasatinib, Sunitinib, and Sorafenib on mitochondrial function in Isolated rat heart mitochondria and H9c2 cells. Toxicological Sciences, 106(1), 153–161.
26. D’Uva, G., Aharonov, A., Lauriola, M., et al. (2015). ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation. Nature Cell Biology, 17(5), 627–638.
27. Crone, S. A., Zhao, Y.-Y., Fan, L., et al. (2002). ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Medicine, 8(5), 459–465.
28. Özcelik, C., Erdmann, B., Pilz, B., et al. (2002). Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proceedings of the National Academy of Sciences, 99(13), 8880–8885.
29. DeBosch, B., Treskov, I., Lupu, T. S., et al. (2006). Akt1 is required for physiological cardiac growth. Circulation, 113(17), 2097–2104.
30. Hardt, S. E., & Sadoshima, J. (2002). Glycogen synthase kinase-3β. Circulation Research, 90(10), 1055–1063.
31. Matsuda, T., Zhai, P., Maejima, Y., et al. (2008). Distinct roles of GSK-3α and GSK-3β phosphorylation in the heart under pressure overload. Proceedings of the National Academy of Sciences, 105(52), 20900–20905.
32. Gordon, L. I., Burke, M. A., Singh, A. T. K., et al. (2009). Blockade of the erbB2 receptor induces Cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. The Journal of Biological Chemistry, 284(4), 2080–2087.
33. Lal, H., Ahmad, F., Woodgett, J., & Force, T. (2015). The GSK-3 family as therapeutic target for myocardial diseases. Circulation Research, 116(1), 138–149.
34. Orphanos, G. S., Ioannidis, G. N., & Ardavanis, A. G. (2009). Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncologica, 48(7), 964–970.
35. Force, T., Krause, D. S., & Van Etten, R. A. (2007). Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nature Reviews. Cancer, 7(5), 332–344.
36. Tan-Chiu, E., Yothers, G., Romond, E., et al. (2005). Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 23(31), 7811–7819.
37. Bowles, E. J. A., Wellman, R., Feigelson, H. S., et al. (2012). Risk of heart failure in breast cancer patients after Anthracycline and Trastuzumab treatment: A retrospective cohort study. Journal of the National Cancer Institute, 104(17), 1293–1305.
38. Sengupta, P. P., Northfelt, D. W., Gentile, F., Zamorano, J. L., & Khandheria, B. K. (2008). Trastuzumab-induced Cardiotoxicity: Heart failure at the crossroads. Mayo Clinic Proceedings, 83(2), 197–203.
39. McArthur, H. L., & Chia, S. (2007). Cardiotoxicity of Trastuzumab in clinical practice. The New England Journal of Medicine, 357(1), 94–95.
40. Telli, M. L., Witteles, R. M., Fisher, G. A., & Srinivas, S. (2008). Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Annals of Oncology, 19(9), 1613–1618.
41. Hasinoff, B. B., Patel, D., & O’Hara, K. A. (2008). Mechanisms of Myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor Sunitinib. Molecular Pharmacology, 74(6), 1722–1728.
42. Schmidinger, M., Zielinski, C. C., Vogl, U. M., et al. (2008). Cardiac toxicity of Sunitinib and Sorafenib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 26(32), 5204–5212.
43. Macarron, R., Banks, M. N., Bojanic, D., et al. (2011). Impact of high-throughput screening in biomedical research. Nature Reviews. Drug Discovery, 10(3), 188–195.
44. Mandenius, C.-F., Steel, D., Noor, F., et al. (2011). Cardiotoxicity testing using pluripotent stem cell-derived human cardiomyocytes and state-of-the-art bioanalytics: A review. Journal of Applied Toxicology, 31(3), 191–205.
45. Chen, M. X., Sandow, S. L., Doceul, V., et al. (2007). Improved functional expression of recombinant human ether-a-go-go (hERG) K+channels by cultivation at reduced temperature. BMC Biotechnology, 7, 93.
46. Lu, H. R., Mariën, R., Saels, A., & De Clerck, F. (2001). Species plays an important role in drug-induced prolongation of action potential duration and early Afterdepolarizations in Isolated Purkinje fibers. Journal of Cardiovascular Electrophysiology, 12(1), 93–102.
47. Ma, J., Guo, L., Fiene, S. J., et al. (2011). High purity human-induced pluripotent stem cell-derived cardiomyocytes: Electrophysiological properties of action potentials and ionic currents. American Journal of Physiology. Heart and Circulatory Physiology, 301(5), H2006–H2017.
48. Liang P, Lan F, Lee AS, et al. (2013) Drug Screening Using a Library of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Reveals Disease Specific Patterns of Cardiotoxicity. Circulation;CIRCULATIONAHA.113.001883.
49. Ackerman, M. J. (1998). The long QT syndrome: Ion Channel diseases of the heart. Mayo Clinic Proceedings, 73(3), 250–269.
50. Moss, A. J., Zareba, W., Kaufman, E. S., et al. (2002). Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go–related Gene Potassium Channel. Circulation, 105(7), 794–799.
51. Nattel, S., Maguy, A., Bouter, S. L., & Yeh, Y.-H. (2007). Arrhythmogenic Ion-Channel remodeling in the heart: Heart failure, myocardial infarction, and atrial fibrillation. Physiological Reviews, 87(2), 425–456.
52. Yu, H., Li, M., Wang, W., & Wang, X. (2016). High throughput screening technologies for ion channels. Acta Pharmacologica Sinica, 37(1), 34–43.
53. Braam, S. R., Tertoolen, L., van de Stolpe, A., Meyer, T., Passier, R., & Mummery, C. L. (2010). Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Research, 4(2), 107–116.
54. Caspi, O., Itzhaki, I., Kehat, I., et al. (2008). In vitro electrophysiological drug testing using human embryonic stem cell derived Cardiomyocytes. Stem Cells and Development, 18(1), 161–172.
55. Harris K, Aylott M, Cui Y, Louttit JB, McMahon NC, Sridhar A. (2013) Comparison of Electrophysiological Data From Human-Induced Pluripotent Stem Cell–Derived Cardiomyocytes to Functional Preclinical Safety Assays. Toxicol Sci;kft113.
56. Natarajan, A., Stancescu, M., Dhir, V., et al. (2011). Patterned cardiomyocytes on microelectrode arrays as a functional, high information content drug screening platform. Biomaterials, 32(18), 4267–4274.
57. Spurgeon, H. A., Stern, M. D., Baartz, G., et al. (1990). Simultaneous measurement of Ca2+, contraction, and potential in cardiac myocytes. The American Journal of Physiology - Heart and Circulatory Physiology, 258(2), H574–H586.
58. Sirenko, O., Crittenden, C., Callamaras, N., et al. (2013). Multiparameter in vitro assessment of compound effects on cardiomyocyte physiology using iPSC cells. Journal of Biomolecular Screening, 18(1), 39–53.
59. Pointon, A., Harmer, A. R., Dale, I. L., et al. (2015). Assessment of Cardiomyocyte contraction in human-induced pluripotent stem cell-derived Cardiomyocytes. Toxicological Sciences, 144(2), 227–237.
60. Grimm, F. A., Iwata, Y., Sirenko, O., Bittner, M., & Rusyn, I. (2015). High-content assay multiplexing for toxicity screening in induced pluripotent stem cell-derived Cardiomyocytes and hepatocytes. Assay and Drug Development Technologies, 13(9), 529–546.
61. Park, J., Ryu, J., Choi, S. K., et al. (2005). Real-time measurement of the contractile forces of self-organized Cardiomyocytes on hybrid biopolymer Microcantilevers. Analytical Chemistry, 77(20), 6571–6580.
62. Grosberg, A., Alford, P. W., McCain, M. L., & Parker, K. K. (2011). Ensembles of engineered cardiac tissues for physiological and pharmacological study: Heart on a chip. Lab on a Chip, 11(24), 4165–4173.
63. Ribeiro, M. C., Tertoolen, L. G., Guadix, J. A., et al. (2015). Functional maturation of human pluripotent stem cell derived cardiomyocytes in vitro – Correlation between contraction force and electrophysiology. Biomaterials, 51, 138–150.
64. Maltman, D. J., & Przyborski, S. A. (2010). Developments in three-dimensional cell culture technology aimed at improving the accuracy of in vitro analyses. Biochemical Society Transactions, 38(4), 1072–1075.
65. Bellis, A. D., Bernabé, B. P., Weiss, M. S., et al. (2013). Dynamic transcription factor activity profiling in 2D and 3D cell cultures. Biotechnology and Bioengineering, 110(2), 563–572.
66. Boudou, T., Legant, W. R., Mu, A., et al. (2011). A Microfabricated platform to measure and Manipulate the mechanics of engineered cardiac Microtissues. Tissue Engineering. Part A, 18(9–10), 910–919.
67. Vandenburgh, H., Shansky, J., Benesch-Lee, F., et al. (2008). Drug-screening platform based on the contractility of tissue-engineered muscle. Muscle & Nerve, 37(4), 438–447.
68. Feinberg, A. W., Feigel, A., Shevkoplyas, S. S., Sheehy, S., Whitesides, G. M., & Parker, K. K. (2007). Muscular thin films for building actuators and powering devices. Science, 317(5843), 1366–1370.
69. Grosberg, A., Alford, P. W., McCain, M. L., & Kit Parker, K. (2011). Ensembles of engineered cardiac tissues for physiological and pharmacological study: Heart on a chip. Lab on a Chip, 11(24), 4165–4173.
70. Boudou, T., Legant, W. R., Mu, A., et al. (2011). A Microfabricated platform to measure and Manipulate the mechanics of engineered cardiac Microtissues. Tissue Engineering. Part A, 18(9–10), 910–919.
71. Hansen, A., Eder, A., Bönstrup, M., et al. (2010). Development of a drug screening platform based on engineered heart tissue. Circulation Research, 107(1), 35–44.
72. Ramade A, Legant WR, Picart C, Chen CS, Boudou T. Chapter 13 - Microfabrication of a Platform to Measure and Manipulate the Mechanics of Engineered Microtissues [Internet]. In: Théry MP and M, editor. Methods in Cell Biology. Academic Press; 2014 [cited 2016 Dec 29]. p. 191–211.Available from: http://www.sciencedirect.com/science/article/pii/B9780128002810000130
73. Schaaf, S., Shibamiya, A., Mewe, M., et al. (2011). Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PloS One, 6(10), e26397.
74. Vandenburgh, H. (2009). High-content drug screening with engineered musculoskeletal tissues. Tissue Engineering. Part B, Reviews, 16(1), 55–64.
75. Jacob F, Yonis AY, Cuello F, et al. (2016) Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue. PLoS ONE [Internet] [cited 2016 Nov 15];11(2). Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740402/
76. Yang, X., Pabon, L., & Murry, C. E. (2014). Engineering adolescence. Circulation Research, 114(3), 511–523.
77. Zhao Y, Radisic M. (2016) BIOWIRE: Tissue culture and drug screening platform using high fidelity 3D engineered cardiac tissue. Montreal, Quebec.
78. Fedorov, V. V., Lozinsky, I. T., Sosunov, E. A., et al. (2007). Application of blebbistatin as an excitation–contraction uncoupler for electrophysiologic study of rat and rabbit hearts. Heart Rhythm, 4(5), 619–626.
79. Liau, B., Christoforou, N., Leong, K., & Bursac, N. (2011). Pluripotent stem cell-derived cardiac tissue patch with advanced structure and function. Biomaterials, 32(35), 9180–9187.
80. Hinds, S., Bian, W., Dennis, R. G., & Bursac, N. (2011). The role of extracellular matrix composition in structure and function of bioengineered skeletal muscle. Biomaterials, 32(14), 3575–3583.
81. Tian, B., Liu, J., Dvir, T., et al. (2012). Macroporous nanowire nanoelectronic scaffolds for synthetic tissues. Nature Materials, 11(11), 986–994.
82. Feiner, R., Engel, L., Fleischer, S., et al. (2016). Engineered hybrid cardiac patches with multifunctional electronics for online monitoring and regulation of tissue function. Nature Materials, 15(6), 679–685.
83. Matsuhisa, N., Kaltenbrunner, M., Yokota, T., et al. (2015). Printable elastic conductors with a high conductivity for electronic textile applications. Nature Communications, 6, 7461.
84. Chun, K.-Y., Oh, Y., Rho, J., et al. (2010). Highly conductive, printable and stretchable composite films of carbon nanotubes and silver. Nature Nanotechnology, 5(12), 853–857.
85. Lind JU, Busbee TA, Valentine AD, et al. (2016) Instrumented cardiac microphysiological devices via multimaterial three-dimensional printing. Nat Mater [Internet] [cited 2017 Jan 23];advance online publication. Available from: http://www.nature.com/nmat/journal/vaop/ncurrent/full/nmat4782.html
86. Entcheva, E. (2013). Cardiac optogenetics. American Journal of Physiology. Heart and Circulatory Physiology, 304(9), H1179–H1191.
87. Klimas, A., Ambrosi, C. M., Yu, J., Williams, J. C., Bien, H., & Entcheva, E. (2016). OptoDyCE as an automated system for high-throughput all-optical dynamic cardiac electrophysiology. Nature Communications, 7, 11542.
88. Paschos, N. K., Brown, W. E., Eswaramoorthy, R., Hu, J. C., & Athanasiou, K. A. (2015). Advances in tissue engineering through stem cell-based co-culture. Journal of Tissue Engineering and Regenerative Medicine, 9(5), 488–503.
89. Tulloch NL, Muskheli V, Razumova MV, et al. (2011) Growth of Engineered Human Myocardium With Mechanical Loading and Vascular Coculture. Circ Res;CIRCRESAHA.110.237206.
90. Thavandiran, N., Dubois, N., Mikryukov, A., et al. (2013). Design and formulation of functional pluripotent stem cell-derived cardiac microtissues. Proceedings of the National Academy of Sciences, 110(49), E4698–E4707.
91. Laverty, H., Benson, C., Cartwright, E., et al. (2011). How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? British Journal of Pharmacology, 163(4), 675–693.
92. Piccini, J. P., Whellan, D. J., Berridge, B. R., et al. (2009). Current challenges in the evaluation of cardiac safety during drug development: Translational medicine meets the critical path initiative. American Heart Journal, 158(3), 317–326.
93. Vunjak-Novakovic, G., Bhatia, S., Chen, C., & Hirschi, K. (2013). HeLiVa platform: Integrated heart-liver-vascular systems for drug testing in human health and disease. Stem Cell Research & Therapy, 4(1), S8.
94. Maschmeyer, I. (2015). K. Lorenz a, Schimek K, et al. a four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents. Lab on a Chip, 15(12), 2688–2699.
95. Loskill, P., Marcus, S. G., Mathur, A., Reese, W. M., & Healy, K. E. (2015). μOrgano: A Lego®-like Plug & Play System for modular multi-organ-chips. PloS One, 10(10), e0139587.
96. Morgan, A. J. L., Jose, L. H. S., Jamieson, W. D., et al. (2016). Simple and versatile 3D printed microfluidics using fused filament fabrication. PloS One, 11(4), e0152023.
97. Imura, Y., Sato, K., & Yoshimura, E. (2010). Micro Total bioassay system for ingested substances: Assessment of intestinal absorption, hepatic metabolism, and bioactivity. Analytical Chemistry, 82(24), 9983–9988.
98. Mahler, G. J., Esch, M. B., Glahn, R. P., & Shuler, M. L. (2009). Characterization of a gastrointestinal tract microscale cell culture analog used to predict drug toxicity. Biotechnology and Bioengineering, 104(1), 193–205.
99. Hwan Sung, J. (2009). L. Shuler M. A micro cell culture analog (μCCA) with 3-D hydrogel culture of multiple cell lines to assess metabolism-dependent cytotoxicity of anti-cancer drugs. Lab on a Chip, 9(10), 1385–1394.
100. Zhang, C., Zhao, Z., Rahim, N. A. A., van Noort, D., & Yu, H. (2009). Towards a human-on-chip: Culturing multiple cell types on a chip with compartmentalized microenvironments. Lab on a Chip, 9(22), 3185–3192.
101. Polini, A., Prodanov, L., Bhise, N. S., Manoharan, V., Dokmeci, M. R., & Khademhosseini, A. (2014). Organs-on-a-chip: A new tool for drug discovery. Expert Opinion on Drug Discovery, 9(4), 335–352.
102. Esch, M. B., & King, T. L. (2011). Shuler. The role of body-on-a-Chip devices in drug and toxicity studies. Annual Review of Biomedical Engineering, 13(1), 55–72.
103. Moraes, C. (2013). M. Labuz J, M. Leung B, Inoue M, Chun T-H, Takayama S. On being the right size: Scaling effects in designing a human-on-a-chip. Integrative Biology, 5(9), 1149–1161.
104. Wikswo, J. P., III, F. E. B., Cliffel, D. E., et al. (2013). Engineering challenges for instrumenting and controlling integrated organ-on-Chip Systems. IEEE Transactions on Biomedical Engineering, 60(3), 682–690.
105. Feric, N. T., & Radisic, M. (2016). Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues. Advanced Drug Delivery Reviews, 96, 110–134.
106. Soldatow, V. Y., EL, L. C., Griffith, L. G., & Rusyn, I. (2013). In vitro models for liver toxicity testing. Toxicology Research, 2(1), 23–39.
107. Chu, T. F., Rupnick, M. A., Kerkela, R., et al. (2007). Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. The Lancet, 370(9604), 2011–2019.
108. Bilancia, D., Rosati, G., Dinota, A., Germano, D., Romano, R., & Manzione, L. (2007). Lapatinib in breast cancer. Annals of Oncology, 18(suppl 6), vi26–vi30.
109. Perez, E. A., Byrne, J. A., Hammond, I. W., et al. (2006). Results of an analysis of cardiac function in 2,812 patients treated with lapatinib. ASCO Meet Abstr, 24(18_suppl), 583.
110. Ribeiro, A. L., Marcolino, M. S., Bittencourt, H. N. S., et al. (2008). An evaluation of the cardiotoxicity of imatinib mesylate. Leukemia Research, 32(12), 1809–1814.
111. Kerkelä, R., Grazette, L., Yacobi, R., et al. (2006). Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Medicine, 12(8), 908–916.
112. Mego, M., Reckova, M., Obertova, J., Sycova-Mila, Z., Brozmanova, K., & Mardiak, J. (2007). Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma. Annals of Oncology, 18(11), 1906–1907.
113. Lynch, D. R., Kickler, T. S., & Rade, J. J. (2010). Recurrent myocardial infarction associated with gefitinib therapy. Journal of Thrombosis and Thrombolysis, 32(1), 120–124.
114. Kus, T., Aktas, G., Sevinc, A., Kalender, M. E., & Camci, C. (2015). Could erlotinib treatment lead to acute cardiovascular events in patients with lung adenocarcinoma after chemotherapy failure? OncoTargets Ther, 8, 1341–1343.
115. Xu Z, Cang S, Yang T, Liu D. Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy. Hematol Rev [Internet] 2009 [cited 2016 Oct 16];1(1). Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3222244/
116. Kim, T. D., le Coutre, P., Schwarz, M., et al. (2012). Clinical cardiac safety profile of nilotinib. Haematologica, 97(6), 883–889.